Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Synthetic Antigen Gels as Practical Controls for Standardized and Quantitative Immunohistochemistry.

Hötzel KJ, Havnar CA, Ngu HV, Rost S, Liu SD, Rangell LK, Peale FV.

J Histochem Cytochem. 2019 May;67(5):309-334. doi: 10.1369/0022155419832002. Epub 2019 Mar 18.

PMID:
30879407
2.

A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition.

Biehs B, Dijkgraaf GJP, Piskol R, Alicke B, Boumahdi S, Peale F, Gould SE, de Sauvage FJ.

Nature. 2018 Oct;562(7727):429-433. doi: 10.1038/s41586-018-0596-y. Epub 2018 Oct 8.

PMID:
30297801
3.

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.

Italiano A, Infante JR, Shapiro GI, Moore KN, LoRusso PM, Hamilton E, Cousin S, Toulmonde M, Postel-Vinay S, Tolaney S, Blackwood EM, Mahrus S, Peale FV, Lu X, Moein A, Epler J, DuPree K, Tagen M, Murray ER, Schutzman JL, Lauchle JO, Hollebecque A, Soria JC.

Ann Oncol. 2018 May 1;29(5):1304-1311. doi: 10.1093/annonc/mdy076.

PMID:
29788155
4.

USP7 small-molecule inhibitors interfere with ubiquitin binding.

Kategaya L, Di Lello P, Rougé L, Pastor R, Clark KR, Drummond J, Kleinheinz T, Lin E, Upton JP, Prakash S, Heideker J, McCleland M, Ritorto MS, Alessi DR, Trost M, Bainbridge TW, Kwok MCM, Ma TP, Stiffler Z, Brasher B, Tang Y, Jaishankar P, Hearn BR, Renslo AR, Arkin MR, Cohen F, Yu K, Peale F, Gnad F, Chang MT, Klijn C, Blackwood E, Martin SE, Forrest WF, Ernst JA, Ndubaku C, Wang X, Beresini MH, Tsui V, Schwerdtfeger C, Blake RA, Murray J, Maurer T, Wertz IE.

Nature. 2017 Oct 26;550(7677):534-538. doi: 10.1038/nature24006. Epub 2017 Oct 18.

PMID:
29045385
5.

Monitoring and Targeting Anti-VEGF Induced Hypoxia within the Viable Tumor by 19F-MRI and Multispectral Analysis.

Shi Y, Oeh J, Hitz A, Hedehus M, Eastham-Anderson J, Peale FV Jr, Hamilton P, O'Brien T, Sampath D, Carano RAD.

Neoplasia. 2017 Nov;19(11):950-959. doi: 10.1016/j.neo.2017.07.010. Epub 2017 Oct 6.

6.

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF.

J Clin Oncol. 2017 Mar 10;35(8):826-833. doi: 10.1200/JCO.2016.70.4320. Epub 2017 Jan 17.

7.

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.

Infante JR, Hollebecque A, Postel-Vinay S, Bauer TM, Blackwood EM, Evangelista M, Mahrus S, Peale FV, Lu X, Sahasranaman S, Zhu R, Chen Y, Ding X, Murray ER, Schutzman JL, Lauchle JO, Soria JC, LoRusso PM.

Clin Cancer Res. 2017 May 15;23(10):2423-2432. doi: 10.1158/1078-0432.CCR-16-1782. Epub 2016 Nov 4.

8.

A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors.

Tolcher AW, Bendell JC, Papadopoulos KP, Burris HA, Patnaik A, Fairbrother WJ, Wong H, Budha N, Darbonne WC, Peale F, Mamounas M, Royer-Joo S, Yu R, Portera CC, Infante JR.

Clin Cancer Res. 2016 Sep 15;22(18):4567-73. doi: 10.1158/1078-0432.CCR-16-0308. Epub 2016 Apr 13.

9.

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.

Punnoose EA, Leverson JD, Peale F, Boghaert ER, Belmont LD, Tan N, Young A, Mitten M, Ingalla E, Darbonne WC, Oleksijew A, Tapang P, Yue P, Oeh J, Lee L, Maiga S, Fairbrother WJ, Amiot M, Souers AJ, Sampath D.

Mol Cancer Ther. 2016 May;15(5):1132-44. doi: 10.1158/1535-7163.MCT-15-0730. Epub 2016 Mar 3.

10.

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.

Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, Saran F, Lai A, Moore N, Kharbanda S, Peale F, Hegde P, Abrey LE, Phillips HS, Bais C.

J Clin Oncol. 2015 Sep 1;33(25):2735-44. doi: 10.1200/JCO.2015.61.5005. Epub 2015 Jun 29. Erratum in: J Clin Oncol. 2016 Sep 1;34(25):3113.

11.

A resource for cell line authentication, annotation and quality control.

Yu M, Selvaraj SK, Liang-Chu MM, Aghajani S, Busse M, Yuan J, Lee G, Peale F, Klijn C, Bourgon R, Kaminker JS, Neve RM.

Nature. 2015 Apr 16;520(7547):307-11. doi: 10.1038/nature14397.

PMID:
25877200
12.

Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma.

Chen R, Nishimura MC, Kharbanda S, Peale F, Deng Y, Daemen A, Forrest WF, Kwong M, Hedehus M, Hatzivassiliou G, Friedman LS, Phillips HS.

Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14217-22. doi: 10.1073/pnas.1409653111. Epub 2014 Sep 15.

13.

Mapping in vivo tumor oxygenation within viable tumor by 19F-MRI and multispectral analysis.

Shi Y, Oeh J, Eastham-Anderson J, Yee S, Finkle D, Peale FV Jr, Ross J, Hedehus M, van Bruggen N, Venook R, Ross S, Sampath D, Carano RA.

Neoplasia. 2013 Nov;15(11):1241-50.

14.

PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.

Metcalfe C, Alicke B, Crow A, Lamoureux M, Dijkgraaf GJ, Peale F, Gould SE, de Sauvage FJ.

Cancer Res. 2013 Dec 1;73(23):7034-42. doi: 10.1158/0008-5472.CAN-13-1222. Epub 2013 Oct 23.

15.

An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy.

Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, Vernes JM, Jiang Z, Meng YG, Peale FV, Ouyang W, Ferrara N.

Nat Med. 2013 Sep;19(9):1114-23. doi: 10.1038/nm.3291. Epub 2013 Aug 4.

16.

Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment.

Phan VT, Wu X, Cheng JH, Sheng RX, Chung AS, Zhuang G, Tran C, Song Q, Kowanetz M, Sambrone A, Tan M, Meng YG, Jackson EL, Peale FV, Junttila MR, Ferrara N.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6079-84. doi: 10.1073/pnas.1303302110. Epub 2013 Mar 25.

17.

Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.

Chung AS, Kowanetz M, Wu X, Zhuang G, Ngu H, Finkle D, Komuves L, Peale F, Ferrara N.

J Pathol. 2012 Aug;227(4):404-16. doi: 10.1002/path.4052. Epub 2012 Jul 3.

PMID:
22611017
18.

Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models.

Wong M, Tan N, Zha J, Peale FV, Yue P, Fairbrother WJ, Belmont LD.

Mol Cancer Ther. 2012 Apr;11(4):1026-35. doi: 10.1158/1535-7163.MCT-11-0693. Epub 2012 Feb 1.

19.

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, Yong WH, Seshagiri S, Modrusan Z, Jiang Z, Aldape KD, Mischel PS, Liau LM, Escovedo CJ, Chen W, Nghiemphu PL, James CD, Prados MD, Westphal M, Lamszus K, Cloughesy T, Phillips HS.

J Clin Oncol. 2011 Dec 1;29(34):4482-90. doi: 10.1200/JCO.2010.33.8715. Epub 2011 Oct 24.

20.
21.

Sustained release formulations of rhVEGF₁₆₅ produce a durable response in a murine model of peripheral angiogenesis.

Daugherty AL, Rangell LK, Eckert R, Zavala-Solorio J, Peale F, Mrsny RJ.

Eur J Pharm Biopharm. 2011 Jun;78(2):289-97. doi: 10.1016/j.ejpb.2011.03.011. Epub 2011 Mar 21.

PMID:
21426936
22.

Robo4 maintains vessel integrity and inhibits angiogenesis by interacting with UNC5B.

Koch AW, Mathivet T, Larrivée B, Tong RK, Kowalski J, Pibouin-Fragner L, Bouvrée K, Stawicki S, Nicholes K, Rathore N, Scales SJ, Luis E, del Toro R, Freitas C, Bréant C, Michaud A, Corvol P, Thomas JL, Wu Y, Peale F, Watts RJ, Tessier-Lavigne M, Bagri A, Eichmann A.

Dev Cell. 2011 Jan 18;20(1):33-46. doi: 10.1016/j.devcel.2010.12.001.

23.

Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes.

Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T, Qu X, Yu L, Ross J, Korsisaari N, Cao T, Bou-Reslan H, Kallop D, Weimer R, Ludlam MJ, Kaminker JS, Modrusan Z, van Bruggen N, Peale FV, Carano R, Meng YG, Ferrara N.

Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21248-55. doi: 10.1073/pnas.1015855107. Epub 2010 Nov 16.

24.

Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis.

Ungersma SE, Pacheco G, Ho C, Yee SF, Ross J, van Bruggen N, Peale FV Jr, Ross S, Carano RA.

Magn Reson Med. 2010 Jun;63(6):1637-47. doi: 10.1002/mrm.22442. Erratum in: Magn Reson Med. 2011 Mar;65(3):889. Magn Reson Med. 2012 Nov;68(5):1681-2. Corrected and republished in: Magn Reson Med. 2011 Mar;65(3):889-99.

25.

Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging.

O'Connor JP, Carano RA, Clamp AR, Ross J, Ho CC, Jackson A, Parker GJ, Rose CJ, Peale FV, Friesenhahn M, Mitchell CL, Watson Y, Roberts C, Hope L, Cheung S, Reslan HB, Go MA, Pacheco GJ, Wu X, Cao TC, Ross S, Buonaccorsi GA, Davies K, Hasan J, Thornton P, del Puerto O, Ferrara N, van Bruggen N, Jayson GC.

Clin Cancer Res. 2009 Nov 1;15(21):6674-82. doi: 10.1158/1078-0432.CCR-09-0731. Epub 2009 Oct 27.

26.

PET of glial metabolism using 2-18F-fluoroacetate.

Marik J, Ogasawara A, Martin-McNulty B, Ross J, Flores JE, Gill HS, Tinianow JN, Vanderbilt AN, Nishimura M, Peale F, Pastuskovas C, Greve JM, van Bruggen N, Williams SP.

J Nucl Med. 2009 Jun;50(6):982-90. doi: 10.2967/jnumed.108.057356. Epub 2009 May 14.

27.

Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site.

Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C, Fuh G.

Science. 2009 Mar 20;323(5921):1610-4. doi: 10.1126/science.1165480.

28.

Reactive hyperemia and BOLD MRI demonstrate that VEGF inhibition, age, and atherosclerosis adversely affect functional recovery in a murine model of peripheral artery disease.

Greve JM, Williams SP, Bernstein LJ, Goldman H, Peale FV Jr, Bunting S, van Bruggen N.

J Magn Reson Imaging. 2008 Oct;28(4):996-1004. doi: 10.1002/jmri.21517.

PMID:
18821600
29.

Quantification of viable tumor microvascular characteristics by multispectral analysis.

Berry LR, Barck KH, Go MA, Ross J, Wu X, Williams SP, Gogineni A, Cole MJ, Van Bruggen N, Fuh G, Peale F, Ferrara N, Ross S, Schwall RH, Carano RA.

Magn Reson Med. 2008 Jul;60(1):64-72. doi: 10.1002/mrm.21470.

30.

Blocking neuropilin-2 function inhibits tumor cell metastasis.

Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, Tong RK, Kowalski J, Ho C, Reslan HB, Ross J, Berry L, Kasman I, Zlot C, Cheng Z, Le Couter J, Filvaroff EH, Plowman G, Peale F, French D, Carano R, Koch AW, Wu Y, Watts RJ, Tessier-Lavigne M, Bagri A.

Cancer Cell. 2008 Apr;13(4):331-42. doi: 10.1016/j.ccr.2008.01.029.

31.

Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1.

Korsisaari N, Ross J, Wu X, Kowanetz M, Pal N, Hall L, Eastham-Anderson J, Forrest WF, Van Bruggen N, Peale FV, Ferrara N.

Clin Cancer Res. 2008 Jan 1;14(1):249-58. doi: 10.1158/1078-0432.CCR-07-1552.

32.

Bv8 regulates myeloid-cell-dependent tumour angiogenesis.

Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, Blanchard D, Bais C, Peale FV, van Bruggen N, Ho C, Ross J, Tan M, Carano RA, Meng YG, Ferrara N.

Nature. 2007 Dec 6;450(7171):825-31.

PMID:
18064003
33.

Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting.

Pan Q, Chathery Y, Wu Y, Rathore N, Tong RK, Peale F, Bagri A, Tessier-Lavigne M, Koch AW, Watts RJ.

J Biol Chem. 2007 Aug 17;282(33):24049-56. Epub 2007 Jun 16.

34.

Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice.

Korsisaari N, Kasman IM, Forrest WF, Pal N, Bai W, Fuh G, Peale FV, Smits R, Ferrara N.

Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10625-30. Epub 2007 Jun 6.

35.

Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons.

Beigneux AP, Davies BS, Gin P, Weinstein MM, Farber E, Qiao X, Peale F, Bunting S, Walzem RL, Wong JS, Blaner WS, Ding ZM, Melford K, Wongsiriroj N, Shu X, de Sauvage F, Ryan RO, Fong LG, Bensadoun A, Young SG.

Cell Metab. 2007 Apr;5(4):279-91.

36.

Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies.

Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV, Fuh G, Olsson C, Damico L, Xie D, Meng YG, Gutierrez J, Corpuz R, Li B, Hall L, Rangell L, Ferrando R, Lowman H, Peale F, Ferrara N.

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3478-83. Epub 2007 Feb 20.

37.

Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth.

Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, Tong RK, Kowalski J, Yee SF, Pacheco G, Ross S, Cheng Z, Le Couter J, Plowman G, Peale F, Koch AW, Wu Y, Bagri A, Tessier-Lavigne M, Watts RJ.

Cancer Cell. 2007 Jan;11(1):53-67.

38.

Hepatocyte growth factor activator inhibitor-1 (HAI-1) is essential for the integrity of basement membranes in the developing placental labyrinth.

Fan B, Brennan J, Grant D, Peale F, Rangell L, Kirchhofer D.

Dev Biol. 2007 Mar 1;303(1):222-30. Epub 2006 Nov 10.

39.

Magnetic resonance angiography reveals therapeutic enlargement of collateral vessels induced by VEGF in a murine model of peripheral arterial disease.

Greve JM, Chico TJ, Goldman H, Bunting S, Peale FV Jr, Daugherty A, van Bruggen N, Williams SP.

J Magn Reson Imaging. 2006 Nov;24(5):1124-32.

PMID:
17029233
40.

Quantitative in situ hybridization of tissue microarrays.

Jubb AM, Pham TQ, Frantz GD, Peale FV Jr, Hillan KJ.

Methods Mol Biol. 2006;326:255-64. Review.

PMID:
16780208
41.

Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma.

Tejada ML, Yu L, Dong J, Jung K, Meng G, Peale FV, Frantz GD, Hall L, Liang X, Gerber HP, Ferrara N.

Clin Cancer Res. 2006 May 1;12(9):2676-88.

42.

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, Fu L, Malik AK, Gerber HP, Ferrara N, Fuh G.

J Biol Chem. 2006 Jan 13;281(2):951-61. Epub 2005 Nov 7.

43.

Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice.

Malik AK, Baldwin ME, Peale F, Fuh G, Liang WC, Lowman H, Meng G, Ferrara N, Gerber HP.

Blood. 2006 Jan 15;107(2):550-7. Epub 2005 Sep 27.

44.

A monoclonal antibody that inhibits mouse tissue factor function.

Kirchhofer D, Moran P, Bullens S, Peale F, Bunting S.

J Thromb Haemost. 2005 May;3(5):1098-9. No abstract available.

45.

Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization.

LeCouter J, Zlot C, Tejada M, Peale F, Ferrara N.

Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16813-8. Epub 2004 Nov 17.

46.

Human endocrine gland-derived vascular endothelial growth factor: expression early in development and in Leydig cell tumors suggests roles in normal and pathological testis angiogenesis.

Samson M, Peale FV Jr, Frantz G, Rioux-Leclercq N, Rajpert-De Meyts E, Ferrara N.

J Clin Endocrinol Metab. 2004 Aug;89(8):4078-88.

PMID:
15292351
47.

VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis.

Dong J, Grunstein J, Tejada M, Peale F, Frantz G, Liang WC, Bai W, Yu L, Kowalski J, Liang X, Fuh G, Gerber HP, Ferrara N.

EMBO J. 2004 Jul 21;23(14):2800-10. Epub 2004 Jul 1.

48.

Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours.

Jubb AM, Pham TQ, Hanby AM, Frantz GD, Peale FV, Wu TD, Koeppen HW, Hillan KJ.

J Clin Pathol. 2004 May;57(5):504-12.

49.

Thyrotropin-releasing hormone is induced in the left ventricle of rats with heart failure and can provide inotropic support to the failing heart.

Jin H, Fedorowicz G, Yang R, Ogasawara A, Peale F, Pham T, Paoni NF.

Circulation. 2004 May 11;109(18):2240-5. Epub 2004 Apr 19.

PMID:
15096458
50.

EG-VEGF and Bv8: a novel family of tissue-restricted angiogenic factors.

Ferrara N, LeCouter J, Lin R, Peale F.

Biochim Biophys Acta. 2004 Mar 4;1654(1):69-78. Review.

PMID:
14984768

Supplemental Content

Support Center